Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Kian Behbakht

Concepts (451)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
44
2025
489
5.500
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
8
2024
90
1.300
 Why?
Peritoneal Neoplasms
7
2024
87
1.120
 Why?
Endometrial Neoplasms
10
2019
164
1.050
 Why?
Drug Resistance, Neoplasm
16
2024
756
0.990
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2020
1555
0.960
 Why?
Uterine Cervical Neoplasms
8
2017
230
0.930
 Why?
Genital Neoplasms, Female
6
2020
82
0.930
 Why?
Cystadenocarcinoma, Serous
6
2024
69
0.840
 Why?
Hysterectomy
4
2018
118
0.760
 Why?
Antineoplastic Agents
10
2023
2053
0.750
 Why?
Fallopian Tube Neoplasms
6
2024
15
0.720
 Why?
TNF-Related Apoptosis-Inducing Ligand
5
2017
44
0.670
 Why?
Biomarkers, Tumor
8
2019
1173
0.620
 Why?
Gelatin
2
2016
42
0.620
 Why?
Neoplasms, Glandular and Epithelial
3
2015
35
0.600
 Why?
Models, Economic
1
2018
53
0.590
 Why?
Thrombin
2
2016
145
0.590
 Why?
Claudin-4
4
2025
15
0.570
 Why?
Hyperthermia, Induced
1
2018
109
0.560
 Why?
Female
84
2025
68543
0.520
 Why?
Pelvic Infection
1
2016
4
0.520
 Why?
Cell Line, Tumor
20
2025
3201
0.520
 Why?
Homeodomain Proteins
3
2012
495
0.520
 Why?
Tissue Adhesives
1
2016
17
0.510
 Why?
Cost-Benefit Analysis
1
2018
569
0.490
 Why?
Neoplastic Cells, Circulating
2
2017
70
0.480
 Why?
Women
1
2015
52
0.460
 Why?
Neoplasm Recurrence, Local
6
2019
958
0.450
 Why?
Sirolimus
2
2016
266
0.430
 Why?
Vagina
6
2016
174
0.420
 Why?
Health Knowledge, Attitudes, Practice
2
2015
1276
0.390
 Why?
Antibodies, Neoplasm
1
2012
34
0.380
 Why?
Neoplasm Staging
15
2024
1290
0.380
 Why?
Humans
88
2025
129248
0.380
 Why?
Middle Aged
47
2024
31087
0.370
 Why?
Cisplatin
2
2015
299
0.370
 Why?
Histone-Lysine N-Methyltransferase
2
2024
124
0.350
 Why?
Aged
35
2024
22032
0.330
 Why?
Neoadjuvant Therapy
4
2020
381
0.330
 Why?
Pelvic Exenteration
1
2009
11
0.320
 Why?
Robotic Surgical Procedures
3
2016
114
0.320
 Why?
Apoptosis
8
2019
2498
0.320
 Why?
Leiomyosarcoma
3
2020
27
0.320
 Why?
Uterine Neoplasms
4
2019
102
0.320
 Why?
Paclitaxel
3
2019
217
0.320
 Why?
Phthalazines
2
2019
41
0.310
 Why?
Cytoreduction Surgical Procedures
2
2020
60
0.310
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
3
2017
29
0.310
 Why?
Aged, 80 and over
17
2020
7055
0.310
 Why?
Health Personnel
1
2015
648
0.310
 Why?
Pyrimidines
3
2019
459
0.310
 Why?
Tumor Microenvironment
2
2024
631
0.300
 Why?
Carcinoma, Endometrioid
3
2019
47
0.300
 Why?
Chemotherapy, Adjuvant
2
2020
379
0.290
 Why?
Caffeine
1
2008
62
0.290
 Why?
Carbazoles
1
2008
84
0.290
 Why?
Azepines
2
2019
88
0.290
 Why?
Clinical Competence
1
2015
1016
0.280
 Why?
Papanicolaou Test
2
2004
42
0.280
 Why?
Vaginal Smears
2
2004
55
0.270
 Why?
Postoperative Complications
6
2020
2473
0.270
 Why?
Piperazines
2
2019
341
0.270
 Why?
Protein Kinase C
1
2008
260
0.270
 Why?
Gene Expression Regulation, Neoplastic
7
2025
1344
0.250
 Why?
Adult
29
2020
35495
0.250
 Why?
Hemostasis, Surgical
2
2016
22
0.240
 Why?
Laparotomy
2
2015
106
0.230
 Why?
Adenocarcinoma
4
2015
898
0.230
 Why?
Urban Health
1
2004
79
0.230
 Why?
Genomic Instability
1
2025
48
0.230
 Why?
Disease-Free Survival
7
2017
645
0.230
 Why?
Fallopian Tubes
1
2024
31
0.220
 Why?
Prognosis
9
2024
3772
0.210
 Why?
Histocompatibility Antigens
2
2024
107
0.210
 Why?
Pyrazoles
2
2020
404
0.210
 Why?
Genetic Therapy
2
2014
288
0.210
 Why?
Uterine Cervical Dysplasia
2
2003
42
0.200
 Why?
Adenocarcinoma, Clear Cell
2
2021
14
0.200
 Why?
Neoplasm Grading
5
2024
283
0.190
 Why?
Leiomyoma
2
2019
73
0.190
 Why?
Healthcare Disparities
2
2018
575
0.180
 Why?
Hospitals, Public
1
2001
26
0.180
 Why?
BRCA2 Protein
3
2019
53
0.180
 Why?
Piperidines
2
2019
198
0.180
 Why?
Hospitals, University
1
2001
179
0.170
 Why?
Vulvar Neoplasms
1
2020
12
0.170
 Why?
Treatment Outcome
11
2020
10199
0.170
 Why?
Cervix Uteri
3
2011
49
0.170
 Why?
Mutation
5
2019
3710
0.170
 Why?
Epoxy Compounds
1
2020
32
0.170
 Why?
Carnitine O-Palmitoyltransferase
1
2020
45
0.160
 Why?
Rad51 Recombinase
1
2019
13
0.160
 Why?
Cell Movement
2
2016
944
0.160
 Why?
Enoxaparin
1
2020
59
0.160
 Why?
Neoplasms
4
2017
2449
0.160
 Why?
Up-Regulation
2
2020
839
0.160
 Why?
Vaccines, Conjugate
1
2019
63
0.160
 Why?
Receptors, Adiponectin
1
2019
19
0.160
 Why?
Poly(ADP-ribose) Polymerases
1
2019
94
0.160
 Why?
Interleukin-12
2
2014
118
0.150
 Why?
Sequence Analysis, RNA
2
2019
428
0.150
 Why?
Pyridones
1
2020
159
0.150
 Why?
CD8-Positive T-Lymphocytes
1
2024
857
0.150
 Why?
Patient Acceptance of Health Care
1
2004
757
0.150
 Why?
Lymph Node Excision
2
2020
164
0.150
 Why?
Adjuvants, Immunologic
1
2019
221
0.150
 Why?
Cancer Vaccines
1
2019
164
0.150
 Why?
Ovariectomy
2
2015
135
0.150
 Why?
Cost Savings
1
2018
78
0.150
 Why?
Sarcoma
1
2020
176
0.150
 Why?
Oncologists
1
2018
35
0.140
 Why?
Cell Growth Processes
2
2008
52
0.140
 Why?
Breast Neoplasms
4
2019
2140
0.140
 Why?
Pregnancy Complications, Infectious
1
2002
367
0.140
 Why?
Dose-Response Relationship, Drug
4
2008
2008
0.140
 Why?
Aurora Kinase A
1
2017
54
0.140
 Why?
Antineoplastic Agents, Phytogenic
1
2019
187
0.140
 Why?
Leukocyte Common Antigens
1
2017
82
0.140
 Why?
beta Catenin
1
2019
223
0.140
 Why?
Survival Rate
5
2020
1869
0.140
 Why?
Anion Transport Proteins
1
2017
9
0.140
 Why?
Fatty Acids
1
2020
426
0.130
 Why?
Salpingectomy
2
2015
13
0.130
 Why?
Sexual Dysfunctions, Psychological
1
2017
34
0.130
 Why?
Gestational Trophoblastic Disease
1
2016
5
0.130
 Why?
Curettage
1
2016
8
0.130
 Why?
Keratins
1
2017
175
0.130
 Why?
Animals
13
2024
35307
0.130
 Why?
Megestrol Acetate
1
2016
2
0.130
 Why?
Carcinoma, Neuroendocrine
1
2016
32
0.130
 Why?
Risk Factors
6
2016
9745
0.130
 Why?
Sexual Dysfunction, Physiological
1
2017
64
0.130
 Why?
Minority Groups
1
2018
249
0.130
 Why?
Venous Thromboembolism
1
2020
284
0.130
 Why?
Neoplasms, Squamous Cell
1
1996
4
0.130
 Why?
Colony Count, Microbial
1
2016
117
0.130
 Why?
Standard of Care
1
2016
71
0.130
 Why?
Medroxyprogesterone Acetate
1
2015
35
0.130
 Why?
Adenoviridae
1
1996
192
0.120
 Why?
Gynecology
1
2018
174
0.120
 Why?
Brachytherapy
1
2016
104
0.120
 Why?
Cell Survival
4
2025
1074
0.120
 Why?
Gene Expression Profiling
2
2019
1688
0.120
 Why?
Anticoagulants
1
2020
636
0.120
 Why?
Keratin-5
1
2015
50
0.120
 Why?
Molecular Targeted Therapy
1
2018
390
0.120
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2017
947
0.120
 Why?
Tamoxifen
1
2016
199
0.120
 Why?
Tretinoin
1
1996
130
0.120
 Why?
Chemoradiotherapy
1
2016
208
0.120
 Why?
Immunohistochemistry
3
2016
1691
0.120
 Why?
Combined Modality Therapy
4
2020
1199
0.120
 Why?
Mice
9
2024
16915
0.120
 Why?
Antineoplastic Agents, Hormonal
1
2015
157
0.120
 Why?
CA-125 Antigen
2
2008
15
0.110
 Why?
Abdominal Abscess
1
2014
26
0.110
 Why?
Surgeons
1
2018
260
0.110
 Why?
Mice, SCID
2
2012
350
0.110
 Why?
Reoperation
1
2016
541
0.110
 Why?
Kaplan-Meier Estimate
4
2020
851
0.110
 Why?
Immunotherapy
1
2018
592
0.110
 Why?
Lipid Metabolism
1
2017
497
0.110
 Why?
Endometrium
1
2014
60
0.110
 Why?
Glycoproteins
1
2015
338
0.110
 Why?
Cytokines
1
2002
2013
0.110
 Why?
Cell Cycle
2
2025
589
0.110
 Why?
Quality of Health Care
1
2018
602
0.110
 Why?
Interpersonal Relations
1
2017
391
0.110
 Why?
Transforming Growth Factor beta
1
1996
455
0.110
 Why?
Proto-Oncogene Proteins c-akt
2
2016
431
0.100
 Why?
Pelvic Neoplasms
1
2013
19
0.100
 Why?
Models, Biological
3
2019
1722
0.100
 Why?
Young Adult
5
2020
12388
0.100
 Why?
Antigens, CD
1
2015
489
0.100
 Why?
Plasmids
1
2014
358
0.100
 Why?
Genes, Tumor Suppressor
3
1998
86
0.100
 Why?
RNA, Messenger
2
2012
2703
0.100
 Why?
Escherichia coli
1
2016
766
0.100
 Why?
Gardnerella vaginalis
2
2002
4
0.100
 Why?
Antibody Specificity
1
2012
184
0.090
 Why?
Neoplastic Stem Cells
1
2015
379
0.090
 Why?
Cell Division
2
2008
796
0.090
 Why?
Endocrine Gland Neoplasms
1
2011
1
0.090
 Why?
Transplantation, Heterologous
1
2012
192
0.090
 Why?
RNA, Small Interfering
3
2020
591
0.090
 Why?
Cyclin D1
1
2011
63
0.090
 Why?
Drug Synergism
2
2011
370
0.090
 Why?
Proteasome Inhibitors
1
2011
42
0.090
 Why?
MicroRNAs
1
2017
676
0.090
 Why?
Adenocarcinoma, Mucinous
1
2011
74
0.090
 Why?
DNA
1
2017
1396
0.090
 Why?
Peptides
1
2015
923
0.080
 Why?
Transfection
2
2007
915
0.080
 Why?
Cell Proliferation
4
2019
2374
0.080
 Why?
Cadherins
1
2011
188
0.080
 Why?
Neoplasm Invasiveness
3
2016
483
0.080
 Why?
Lymphoma
1
2011
196
0.080
 Why?
Inflammation
1
2020
2737
0.080
 Why?
Age Factors
5
2016
3140
0.080
 Why?
Skin Transplantation
1
2009
84
0.080
 Why?
Anastomosis, Surgical
1
2009
149
0.080
 Why?
Adolescent
5
2020
20303
0.080
 Why?
Adaptor Proteins, Signal Transducing
1
2011
399
0.080
 Why?
Urokinase-Type Plasminogen Activator
1
2008
29
0.080
 Why?
Papillomaviridae
2
2002
114
0.080
 Why?
G2 Phase
1
2008
36
0.070
 Why?
TOR Serine-Threonine Kinases
1
2011
396
0.070
 Why?
Radiation-Protective Agents
1
2008
26
0.070
 Why?
Rectum
1
2009
170
0.070
 Why?
Case-Control Studies
4
2019
3377
0.070
 Why?
Models, Statistical
1
2011
623
0.070
 Why?
Heterografts
2
2019
131
0.070
 Why?
Genes, BRCA1
2
1998
32
0.070
 Why?
Class I Phosphatidylinositol 3-Kinases
2
2019
81
0.070
 Why?
Microsatellite Instability
2
2019
37
0.070
 Why?
Urinary Bladder
1
2009
175
0.070
 Why?
Cell Culture Techniques
2
2020
336
0.070
 Why?
Xenograft Model Antitumor Assays
2
2020
812
0.070
 Why?
Cysteine
1
2008
195
0.070
 Why?
Tumor Suppressor Protein p53
3
2019
509
0.070
 Why?
Gynecologic Surgical Procedures
2
2020
56
0.070
 Why?
PTEN Phosphohydrolase
2
2019
161
0.060
 Why?
Double-Blind Method
3
2019
1875
0.060
 Why?
Retrospective Studies
6
2020
14455
0.060
 Why?
Proportional Hazards Models
3
2020
1197
0.060
 Why?
Adenosarcoma
2
2005
2
0.060
 Why?
Models, Animal
1
2008
376
0.060
 Why?
Follow-Up Studies
4
2020
4886
0.060
 Why?
Length of Stay
3
2015
1120
0.060
 Why?
Signal Transduction
4
2012
4926
0.060
 Why?
Polymerase Chain Reaction
4
2002
1036
0.060
 Why?
Indazoles
2
2019
66
0.060
 Why?
Colposcopy
2
2003
15
0.060
 Why?
Ovary
1
2007
207
0.060
 Why?
Intestinal Neoplasms
1
2005
28
0.060
 Why?
Cell Count
2
2015
311
0.060
 Why?
Neoplasm Proteins
3
1998
422
0.060
 Why?
United States
5
2022
13828
0.060
 Why?
Germ-Line Mutation
2
1996
140
0.060
 Why?
Ultraviolet Rays
1
2008
382
0.060
 Why?
Sexual Behavior
1
2009
481
0.060
 Why?
Chicago
1
2004
57
0.060
 Why?
Disease Progression
3
2019
2630
0.060
 Why?
Tumor Cells, Cultured
2
1996
942
0.060
 Why?
Peptide Fragments
1
2008
692
0.060
 Why?
Antioxidants
1
2008
558
0.060
 Why?
Transcription Factors
4
2011
1647
0.060
 Why?
Blood Loss, Surgical
2
2015
93
0.060
 Why?
Survival Analysis
4
2020
1269
0.050
 Why?
Activating Transcription Factor 6
1
2023
17
0.050
 Why?
Receptors, Estrogen
2
2015
426
0.050
 Why?
Transcription Factor AP-1
1
2023
88
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2022
13
0.050
 Why?
Neoplasm Metastasis
2
2015
610
0.050
 Why?
Medical Oncology
1
2024
270
0.050
 Why?
Risk Assessment
3
2016
3233
0.050
 Why?
Vaginal Neoplasms
1
2001
12
0.050
 Why?
Trichomonas vaginalis
1
2002
13
0.050
 Why?
Gene Expression
1
2007
1466
0.050
 Why?
Phosphatidylinositol 3-Kinases
2
2016
360
0.050
 Why?
Yeasts
1
2002
52
0.050
 Why?
Women's Health
1
2004
364
0.050
 Why?
Vaginosis, Bacterial
1
2001
12
0.050
 Why?
Cell Nucleus
1
2025
586
0.050
 Why?
Vaginal Diseases
1
2001
21
0.050
 Why?
Pregnancy
3
2016
6391
0.050
 Why?
Endometriosis
1
2001
46
0.040
 Why?
DNA, Neoplasm
2
1998
158
0.040
 Why?
DNA Primers
1
2002
510
0.040
 Why?
Vulvectomy
1
2020
2
0.040
 Why?
Epithelial Cells
1
2007
1063
0.040
 Why?
Histiocytoma, Malignant Fibrous
1
2020
5
0.040
 Why?
Databases, Factual
2
2016
1266
0.040
 Why?
Dermatofibrosarcoma
1
2020
9
0.040
 Why?
Hospitals, Urban
1
2001
129
0.040
 Why?
DNA Repair
1
2022
206
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
Alleles
3
2017
845
0.040
 Why?
Medically Uninsured
1
2001
126
0.040
 Why?
Liposarcoma
1
2020
27
0.040
 Why?
Anoikis
1
2020
31
0.040
 Why?
Prospective Studies
4
2016
7121
0.040
 Why?
Hemocyanins
1
2019
62
0.040
 Why?
Interleukin-10
1
2002
300
0.040
 Why?
Diagnosis, Differential
2
2019
1430
0.040
 Why?
Chitinase-3-Like Protein 1
1
2019
19
0.040
 Why?
Rhabdomyosarcoma
1
2020
64
0.040
 Why?
DNA Damage
1
2022
383
0.040
 Why?
Logistic Models
1
2004
1984
0.040
 Why?
Radiotherapy
1
2020
185
0.040
 Why?
SEER Program
1
2020
202
0.040
 Why?
Enzyme-Linked Immunosorbent Assay
1
2002
833
0.040
 Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2019
25
0.040
 Why?
Lymphatic Metastasis
1
2020
320
0.040
 Why?
Intramolecular Oxidoreductases
1
2019
67
0.040
 Why?
Poly-ADP-Ribose Binding Proteins
1
2019
33
0.040
 Why?
DNA Polymerase II
1
2019
38
0.040
 Why?
Gene Knockdown Techniques
1
2020
316
0.040
 Why?
Chromosomes, Human, Pair 7
1
1998
15
0.040
 Why?
Cell Cycle Checkpoints
1
2019
95
0.040
 Why?
Cytoskeletal Proteins
1
2019
146
0.040
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2019
119
0.040
 Why?
Mitosis
1
2019
180
0.040
 Why?
Microtubule-Associated Proteins
1
2019
192
0.040
 Why?
Europe
1
2019
363
0.040
 Why?
AMP-Activated Protein Kinases
1
2019
191
0.040
 Why?
Interleukin-6
1
2002
720
0.040
 Why?
Interleukin-1
1
2002
959
0.040
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
1998
33
0.040
 Why?
Image Cytometry
1
2017
7
0.040
 Why?
Wnt Signaling Pathway
1
2019
170
0.030
 Why?
Chromosomes, Human, Pair 14
1
1997
19
0.030
 Why?
Ganciclovir
1
1996
52
0.030
 Why?
Chromosome Deletion
1
1997
104
0.030
 Why?
Socioeconomic Factors
1
2001
1209
0.030
 Why?
Hospitals, Private
1
2016
12
0.030
 Why?
Health Facility Size
1
2016
11
0.030
 Why?
Time Factors
2
2019
6543
0.030
 Why?
Chorionic Gonadotropin
1
2016
79
0.030
 Why?
Oxidation-Reduction
1
2020
1028
0.030
 Why?
Mass Spectrometry
1
2019
713
0.030
 Why?
Indoles
1
2019
384
0.030
 Why?
Cell Differentiation
2
2011
1887
0.030
 Why?
Ifosfamide
1
1996
34
0.030
 Why?
AC133 Antigen
1
2015
19
0.030
 Why?
Cell Separation
1
2017
316
0.030
 Why?
Cell Line, Transformed
1
1996
140
0.030
 Why?
Marriage
1
2017
113
0.030
 Why?
RNA-Binding Proteins
1
2019
387
0.030
 Why?
Tissue Array Analysis
1
2015
57
0.030
 Why?
Hospital Charges
1
1996
41
0.030
 Why?
Hospitals, Teaching
1
2016
113
0.030
 Why?
Caspase 3
1
2016
245
0.030
 Why?
Cystadenocarcinoma, Papillary
1
1995
5
0.030
 Why?
Carboplatin
1
1996
139
0.030
 Why?
Tumor Burden
1
2016
286
0.030
 Why?
Cell Cycle Proteins
1
2019
584
0.030
 Why?
Disease Management
1
2019
588
0.030
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2015
66
0.030
 Why?
DNA Mismatch Repair
1
2015
47
0.030
 Why?
Ileus
1
2015
12
0.030
 Why?
Genes, p53
1
1995
70
0.030
 Why?
Income
1
2016
188
0.030
 Why?
Urinary Retention
1
2015
20
0.030
 Why?
Elective Surgical Procedures
1
2016
164
0.030
 Why?
Female Urogenital Diseases
1
2014
5
0.030
 Why?
RNA Interference
1
2016
450
0.030
 Why?
Taxoids
1
2015
98
0.030
 Why?
Antigens, Neoplasm
1
2017
308
0.030
 Why?
Morbidity
1
2015
300
0.030
 Why?
Intraoperative Complications
1
2015
129
0.030
 Why?
Sensitivity and Specificity
1
2019
1837
0.030
 Why?
Receptors, Androgen
1
2015
147
0.030
 Why?
Multivariate Analysis
2
1996
1497
0.030
 Why?
Drug Administration Schedule
1
2016
768
0.030
 Why?
Histones
1
2019
588
0.030
 Why?
Blood Volume
1
2014
60
0.030
 Why?
Reference Values
1
1996
793
0.030
 Why?
Bevacizumab
1
2015
129
0.030
 Why?
Bleomycin
1
1996
242
0.030
 Why?
Point Mutation
1
1995
224
0.030
 Why?
Infusions, Parenteral
1
2014
38
0.030
 Why?
Polyethyleneimine
1
2014
18
0.030
 Why?
Hemostatics
1
2014
49
0.030
 Why?
Pelvis
1
2015
104
0.030
 Why?
DNA, Viral
1
1996
349
0.030
 Why?
Deoxycytidine
1
2015
165
0.030
 Why?
Insurance, Health
1
2016
265
0.030
 Why?
Tumor Suppressor Proteins
1
2016
314
0.030
 Why?
Receptors, Progesterone
1
2015
343
0.030
 Why?
Drainage
1
2014
164
0.030
 Why?
Anemia
1
2015
160
0.030
 Why?
Lipids
1
2017
625
0.030
 Why?
Preoperative Care
1
2015
339
0.030
 Why?
Urban Population
1
2016
441
0.030
 Why?
Thrombocytopenia
1
2015
186
0.030
 Why?
Gene Transfer Techniques
1
2014
161
0.030
 Why?
Patient Readmission
1
2018
652
0.030
 Why?
Referral and Consultation
1
2018
727
0.030
 Why?
Polymorphism, Single-Stranded Conformational
3
1998
28
0.030
 Why?
Ultrasonography
1
2016
713
0.020
 Why?
Membrane Proteins
1
2019
1117
0.020
 Why?
Biomarkers
1
2024
3966
0.020
 Why?
Linear Models
1
1994
819
0.020
 Why?
Rural Population
1
2016
513
0.020
 Why?
Cholesterol
1
2014
412
0.020
 Why?
Zinc Finger E-box-Binding Homeobox 1
1
2011
24
0.020
 Why?
Perioperative Period
1
2011
49
0.020
 Why?
Analysis of Variance
1
1994
1288
0.020
 Why?
Protein Kinase Inhibitors
1
2017
890
0.020
 Why?
Mutant Proteins
1
2011
99
0.020
 Why?
Comorbidity
1
2016
1544
0.020
 Why?
DNA Fragmentation
1
2011
44
0.020
 Why?
Risk Reduction Behavior
1
2013
209
0.020
 Why?
Fas Ligand Protein
1
2011
59
0.020
 Why?
Tomography, X-Ray Computed
2
2014
2515
0.020
 Why?
Hyperplasia
1
2011
171
0.020
 Why?
Neovascularization, Pathologic
1
2012
296
0.020
 Why?
Neoplasm Transplantation
1
2011
256
0.020
 Why?
Administration, Oral
1
2012
785
0.020
 Why?
Polymorphism, Single Nucleotide
1
2017
2063
0.020
 Why?
Antibodies, Monoclonal, Humanized
1
2015
758
0.020
 Why?
Epithelial-Mesenchymal Transition
1
2011
201
0.020
 Why?
Pregnancy Complications
1
2014
493
0.020
 Why?
Anti-Bacterial Agents
2
2014
1702
0.020
 Why?
Polyethylene Glycols
1
2014
587
0.020
 Why?
Regression Analysis
1
2011
991
0.020
 Why?
Receptors, Urokinase Plasminogen Activator
1
2008
15
0.020
 Why?
Patient Discharge
1
2015
835
0.020
 Why?
Quality of Life
1
2020
2685
0.020
 Why?
Injections, Subcutaneous
1
2008
147
0.020
 Why?
Blotting, Western
1
2011
1204
0.020
 Why?
Placebos
1
2008
201
0.020
 Why?
Mice, Hairless
1
2008
60
0.020
 Why?
Enzyme Inhibitors
1
2011
827
0.020
 Why?
Sulfonamides
1
2011
495
0.020
 Why?
Quality Improvement
1
2015
1095
0.020
 Why?
Molecular Sequence Data
3
1996
2835
0.020
 Why?
Chromosome Mapping
2
1998
504
0.020
 Why?
Genetic Markers
2
1998
336
0.020
 Why?
Disease Models, Animal
1
2016
4057
0.020
 Why?
Receptors, Cell Surface
1
2008
380
0.020
 Why?
Frameshift Mutation
2
1996
32
0.020
 Why?
Cross-Sectional Studies
1
2017
5045
0.020
 Why?
Gene Deletion
2
1998
380
0.020
 Why?
Carcinosarcoma
1
2005
17
0.020
 Why?
Cohort Studies
1
2015
5408
0.010
 Why?
DNA Mutational Analysis
2
1996
385
0.010
 Why?
Colorado
1
2014
4406
0.010
 Why?
Severity of Illness Index
1
2011
2737
0.010
 Why?
Obesity
1
2016
2879
0.010
 Why?
Base Sequence
2
1996
2146
0.010
 Why?
Electrophoresis, Gel, Pulsed-Field
1
2001
21
0.010
 Why?
Metronidazole
1
2001
20
0.010
 Why?
Genes, rRNA
1
2001
41
0.010
 Why?
Microbial Sensitivity Tests
1
2001
347
0.010
 Why?
DNA, Bacterial
1
2001
321
0.010
 Why?
RNA, Ribosomal, 16S
1
2001
522
0.010
 Why?
Loss of Heterozygosity
1
1998
46
0.010
 Why?
Microsatellite Repeats
1
1998
164
0.010
 Why?
Actuarial Analysis
1
1996
26
0.010
 Why?
Ecosystem
1
2001
556
0.010
 Why?
Genes, Neoplasm
1
1995
20
0.010
 Why?
BRCA1 Protein
1
1995
65
0.010
 Why?
Sequence Analysis, DNA
1
1998
776
0.010
 Why?
Age of Onset
1
1996
496
0.010
 Why?
Introns
1
1995
251
0.010
 Why?
Exons
1
1995
341
0.010
 Why?
Amino Acid Sequence
1
1995
2056
0.010
 Why?
Male
1
2017
63501
0.010
 Why?
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (451) concept(s)
_
Co-Authors Expand Description
See all (57) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)